Literature DB >> 8701078

Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes.

K S Korach1, J F Couse, S W Curtis, T F Washburn, J Lindzey, K S Kimbro, E M Eddy, S Migliaccio, S M Snedeker, D B Lubahn, D W Schomberg, E P Smith.   

Abstract

The estrogen receptor (ER) is thought to play a crucial role in the regulation of many life processes, including development, reproduction and normal physiology. Because there have been no known mutations of the estrogen receptor in normal tissue of humans and animals, its presence and tissue distribution is thought to be essential for survival. Using the techniques of homologous recombination, we have disrupted the ER gene and have produced a line of transgenic mice possessing the altered ER gene (ERKO). The mouse ER gene was disrupted by inserting a 1.8 kb PGK-Neomycin sequence into exon 2, approximately 280 bp downstream of the transcription start codon. The correct targeting of the disruption was demonstrated by Southern blot analysis and PCR. Western blot analysis of uterine preparations from ERKO females showed no detectable ER protein. Heterozygotes had one half the level of ER protein compared to wild-type animals. Estrogen insensitivity was confirmed using estrogen agonists, estradiol, hydroxy tamoxifen, diethylstilbestrol treatment for 3 days which resulted in a 3-4-fold increase in uterine wet weight and vaginal cornification in wild-type females, while ERKO mice were totally unresponsive. These data were further supported by the failure of estrogen or EGF treatment to induce DNA synthesis in uterine tissue of similarly treated mice. Lactoferrin, an estrogen-responsive gene in the uterus, was also assayed by Northern blot. Wild-type mice treated with a single estradiol injection showed a 350-fold induction in lactoferrin mRNA. while ERKO females showed no detectable response. Both male and female animals survive to adulthood with normal gross external phenotypes. As expected, females are infertile and demonstrate hypoplastic uteri and hyperemic ovaries with no apparent corpora lutea. Males are also infertile, with atrophy of the testes and seminiferous tubule dysmorphogenesis. Although the reproductive capabilities have been altered with a dramatic effect on the gonads, prenatal development of the reproductive tracts of both sexes appear to be independent of an ER-mediated response. Analysis of the mammary glands of the ERKO females at 4 months of age showed a primitive ductal rudiment rather than the fully developed ductal tree seen in wild-type siblings. Also absent were the terminal end buds seen during normal ductal morphogenesis. Both sexes show a decrease in skeletal bone density, supporting a direct role for ER action in bone. A single patient is described who is homozygous for a point mutation in the human ER gene at codon 157. The mutation produces a truncation of the ER protein and results in estrogen insensitivity syndrome. Most significant of the clinical findings are effects on skeletal bone density and retarded bone age. Findings from the patient and mice suggest that the absence of functional ER is not lethal. Mutation in the ER gene is present in the human population. Further characterization of the mice and identification of additional patients will be required to more fully understand the consequences of ER gene mutations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701078

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  77 in total

Review 1.  Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse.

Authors:  J L Fendrick; A M Raafat; S Z Haslam
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

2.  Immortalization of mammary cells from estrogen receptor alpha knock-out and wild-type mice.

Authors:  S O Mueller; H Tahara; J C Barrett; K S Korach
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

3.  Lactation defect in mice lacking the helix-loop-helix inhibitor Id2.

Authors:  S Mori; S I Nishikawa; Y Yokota
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

4.  Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus.

Authors:  M C Erlandsson; C Ohlsson; J A Gustafsson; H Carlsten
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

Review 5.  Mammary gland development and tumorigenesis in estrogen receptor knockout mice.

Authors:  W P Bocchinfuso; K S Korach
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 6.  Synthetic adipose tissue models for studying mammary gland development and breast tissue engineering.

Authors:  Xiuli Wang; Michaela R Reagan; David L Kaplan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-12       Impact factor: 2.673

7.  GAS6 is an estrogen-inducible gene in mammary epithelial cells.

Authors:  Rigen Mo; Yiwei Tony Zhu; Zhongyi Zhang; Sambasiva M Rao; Yi-Jun Zhu
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

Review 8.  MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer.

Authors:  Rajesh R Singh; Rakesh Kumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2007-09       Impact factor: 2.673

9.  Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction.

Authors:  Carolyn L Smith; Darryll G DeVera; Dolores J Lamb; Zafar Nawaz; Yong-Hui Jiang; Arthur L Beaudet; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

10.  Coactivation of estrogen receptor beta by gonadotropin-induced cofactor GIOT-4.

Authors:  Madoka Kouzu-Fujita; Yoshihiro Mezaki; Shun Sawatsubashi; Takahiro Matsumoto; Ikuko Yamaoka; Tetsu Yano; Yuji Taketani; Hirochika Kitagawa; Shigeaki Kato
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.